Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

215.44
+4.061.92%
Post-market: 216.501.06+0.49%18:59 EDT
Volume:3.52M
Turnover:747.21M
Market Cap:46.18B
PE:-24.15
High:218.30
Open:209.32
Low:198.91
Close:211.38
52wk High:220.34
52wk Low:35.62
Shares:214.34M
Float Shares:184.00M
Volume Ratio:2.21
T/O Rate:1.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:17.72
PE(LYR):-36.21

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

TIPRANKS
·
Aug 06

Revolution Medicines, Inc. : Needham Raises Target Price to $240 from $236

THOMSON REUTERS
·
Aug 06

Revolution Medicines Earns Buy as Strong RAS Portfolio Data, Robust Launch Prep, and $5.4B Capital Base Drive Price Target Increase to $291

TIPRANKS
·
Aug 06

Revolution Medicines Publishes Corporate Deck Outlining Ras(on) Inhibitor Pipeline Targeting RAS-Driven Cancers

Reuters
·
Aug 06

Revolution Medicines Q2 2026 Earnings: Daraxonrasib Advances as Spending Rises

TradingKey
·
Aug 06

Earnings Flash (RVMD) Revolution Medicines Posts Q2 Loss $3.06, vs. FactSet Est of $2.04 Loss

MT Newswires Live
·
Aug 06

Revolution Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Revolution Medicines reports Q2 EPS ($3.06), consensus ($2.06)

TIPRANKS
·
Aug 06

Revolution Medicines Q2 FY26 Net Loss Widens to $644.4 Million; R&D Expenses Rise to $394.9 Million

Reuters
·
Aug 06

Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate

Benzinga Earnings
·
Aug 06

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

THOMSON REUTERS
·
Aug 06

Movement Alert|Revolution Medicines, Inc. Rises 5.23% in Regular Trading, FDA NDA Acceptance and Pre-Earnings Optimism Drive Multi-Catalyst Rally

Market Focus
·
Aug 05

Revolution Medicines Inc Expected to Post a Loss of $1.98 a Share - Earnings Preview

Reuters
·
Aug 04

Jefferies Cuts Ipsen to 'underperform' on Somatuline Competition Risk

Reuters
·
Aug 03

FDA Priority Review For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)

Simply Wall St.
·
Jul 31

Movement Alert|Revolution Medicines, Inc. Rises 5.02% in Regular Trading, FDA Accepts NDA for Pancreatic Cancer Drug as Wedbush Raises Target Price

Market Focus
·
Jul 31

Revolution Medicines to Report Q2 Financial Results After Market Close, Hosts Webcast Update

Reuters
·
Jul 30

Revolution Medicines (RVMD) Is Up 5.3% After FDA Priority Review For Pancreatic Cancer Drug Approval Bid

Simply Wall St.
·
Jul 24

Revolution Medicines is Maintained at Outperform by Wedbush

Dow Jones
·
Jul 23

Movement Alert|Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Core Drug NDA Formally Accepted by FDA

Market Focus
·
Jul 23